Articles

A study using the FDA Adverse Event Reporting System (FAERS) has demonstrated the high cost burden of adverse events (AEs) associated with the use of tyrosine kinase inhibitors (TKIs) in patients with chronic myelogenous leukemia (CML). The results were presented at ASH 2015 by Nicola Wallis, MRCPath, FFPM, Bristol-Myers Squibb, Princeton, NJ.

A higher score on a composite index of homologous recombination deficiency (HRD), indicating genomic instability, correlated with improved progression-free survival (PFS) and overall survival (OS) in patients with ovarian cancer who have received platinum-containing chemotherapy, according to results presented at the 2016 Society of Gynecologic Oncology annual meeting.

The evidence blocks were incorporated into the National Comprehensive Cancer Network (NCCN) clinical practice guidelines late last year and act as a visual representation of 5 key measures related to specific recommendations.

The updated National Comprehensive Cancer Network (NCCN) guideline (version 2.2016) for the management of advanced melanoma reflects the increasing role of immune checkpoint inhibitors and targeted agents, as more data establish their superior efficacy over traditional chemotherapy.

The population of patients with multiple myeloma who are eligible for therapy has been expanded to include asymptomatic patients with certain features, according to the most recent National Comprehensive Cancer Network (NCCN) guideline (version 3.2016).

The oncology National Practice Benchmark (NPB) annual report provides important information regarding oncology providers’ productivity, costs, practice revenues, and profits. Key findings from the 2015 report show that new patient visits and average drug spending are on the rise (Balch C, et al. J Oncol Pract. 2016;12:e437-e475).

The realignment of incentives and enhanced collaboration in cancer research are priorities that would speed the pace of discovery, with the goal to “end cancer as we know,” said Vice President Joe Biden at the 2016 American Association for Cancer Research annual meeting. Mr Biden discussed aspects of the new “Moonshot” initiative to eliminate cancer, which was initiated by President Obama at his 2016 State of the Union Address.

Anti–PD-1 treatment with the PD-1 inhibitor nivolumab (Opdivo) significantly improved survival in patients with head and neck squamous-cell carcinoma that progressed after platinum-based therapy, according to data from a phase 3 clinical trial known as CheckMate-141.